Compulsory Licence for Saxagliptin: Protection versus Competition Harvard Case Solution & Analysis

Compulsory Licence for Saxagliptin: Protection versus Competition Case Solution

The license workplace strictly impose the patent routine, which would motivate greater foreign capital influxes in research study and advancement in the Indian pharmaceutical market and promote developments and developments in the nation? Or needs to it approve the compulsory licence, consequently connecting higher weight to the well-being of India's public? Veena Keshav Pailwar is connected having Institute of Management Technology, Nagpur.

In June 2015, Lee Pharma Limited, a little Indian pharmaceutical business, submitted a request with the Indian Patent Office for a grant of a compulsory permit to produce the diabetes drug Saxagliptin on the reasons that the trademarked variation of the drug had actually not been provided to the general public at a budget friendly cost. The giving of a compulsory licence was really anticipated to make the medication more inexpensive for the public, however it would likewise weaken the rate of interests of the patentee, a Western international business. The circulation of trade and also foreign capital into the nation would be negatively impacted if the industrialized world enforced sanctions versus India in revenge for these sort of a protectionist procedure.

PUBLICATION DATE: August 31, 2016

This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE

Compulsory Licence for Saxagliptin: Protection versus Competition Case Solution Other Similar Case Solutions like

Compulsory Licence for Saxagliptin: Protection versus Competition

Share This